Stefan Rehnmark
Hoofd Techniek/Wetenschap/O&O bij GABATHER AB
Actieve functies van Stefan Rehnmark
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| GABATHER AB | Hoofd Techniek/Wetenschap/O&O | 01-01-2018 | - |
| Corporate Officer/Principal | 01-08-2016 | 01-01-2018 | |
| LIDDS AB | Directeur/Bestuurslid | 27-05-2024 | - |
Loopbaan van Stefan Rehnmark
Eerdere bekende functies van Stefan Rehnmark
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| University of Stockholm | Corporate Officer/Principal | 01-01-1998 | 01-01-1998 |
| Noviga Research AB | Oprichter | - | - |
Axcentua Pharmaceuticals AB
 Axcentua Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Axcentua Pharmaceuticals AB develops anti-cancer drugs for pancreatic cancer patients. It generates investigational new drugs for diseases with unmet medical need in Sweden. The firm offers AXP107-11, multi-targeted chemosensitizer and a small-molecule anti-cancer compound for the treatment of various solid tumors, such as non-small cell lung cancers. The company was founded in 2007 by Anders Berkenstam, Stefan Rehnmark and Michael-Robin Witt and is headquartered in Stockholm, Sweden. | Algemeen Directeur | - | - |
| Hoofd Techniek/Wetenschap/O&O | - | - | |
| Oprichter | 01-01-2007 | - |
Opleiding van Stefan Rehnmark
| University of Stockholm | Doctorate Degree |
Statistieken
Internationaal
| Zweden | 6 |
Operationeel
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 2 |
| Founder | 2 |
Sectoraal
| Health Technology | 4 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| LIDDS AB | Health Technology |
| GABATHER AB | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Axcentua Pharmaceuticals AB
Axcentua Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Axcentua Pharmaceuticals AB develops anti-cancer drugs for pancreatic cancer patients. It generates investigational new drugs for diseases with unmet medical need in Sweden. The firm offers AXP107-11, multi-targeted chemosensitizer and a small-molecule anti-cancer compound for the treatment of various solid tumors, such as non-small cell lung cancers. The company was founded in 2007 by Anders Berkenstam, Stefan Rehnmark and Michael-Robin Witt and is headquartered in Stockholm, Sweden. | Health Technology |
| Noviga Research AB |
- Beurs
- Insiders
- Stefan Rehnmark
- Ervaring
